Lupin Q1 Review: Dolat Capital Maintains 'Add', But Cuts Target Price - Here's Why
Timely launches of injectables and inhalation products will be further triggers to the brokerage's earnings estimates.
Timely launches of injectables and inhalation products will be further triggers to the brokerage's earnings estimates.